The Effectiveness of Moderate-vigorous Intermittent Lifestyle Physical Activity and Health Education to Increase Intense Physical Activity in Stroke Survivors: a Pragmatic Randomised Controlled Trial (MV-ILPA-stroke)

Stroke is the leading cause of disability in Spain. Additionally, it is the second leading cause of death in women and the third in both sexes. Regular physical activity (PA) helps prevent and manage stroke. It also helps with hypertension, maintains a healthy body weight, and improves mental health, quality of life, and well-being. PA plays a prominent role in inpatient care after stroke. However, stroke survivors become more sedentary when discharged from the hospital. They have muscle weakness, reduced balance, and fatigue. Consequently, PA levels of community-dwelling post-stroke individuals remain lower than their age-matched counterparts. Continued PA can help this population maintain and improve physical function, and reduce long-term functional limitations, and mortality risk.

开始日期2025-02-01

申办/合作机构

Universitat Internacional de Catalunya

[+1]

NCT06633237 / Enrolling by invitationN/AIIT

Effectiveness of Core Training on the Biomechanics of Jump Landing in Amateur Female Basketball Players: a Cluster Randomized Controlled Trial

The goal of this clinical trial is to evaluate the effectiveness of a core training intervention on jump-landing biomechanics in female amateur basketball players. Additionally, it will assess the impact of this intervention on jumping performance. The primary questions it aims to answer are:
1. Does a core training intervention reduce jump-landing biomechanics errors, as measured by the Landing Error Scoring System (LESS)?
2. Will the LESS items related to core and trunk stability improve following the core training program?
3. Will the core training program enhance jumping performance in female amateur basketball players?
4. Is there a relationship between poor LESS scoring and poor jumping performance? Researchers will compare the effects of a core training intervention applied during the warm-up in basketball training with the standard warm-up routine typically used at this basketball level.
Participants will be asked to:
* Attend the scheduled assessments at three points during the study: before the intervention begins, at the end of the 8-week intervention period, and after a 3-month follow-up period.
* Teams in the intervention group will incorporate the core training exercises during their warm-up, twice a week, over the 8-week period.
* Teams in the control group will continue their standard warm-up routine without any modifications.
* All participating teams will document the training sessions completed by the players to monitor adherence to the program.

开始日期2024-10-01

申办/合作机构

Universitat Internacional de Catalunya

NCT06535958 / Not yet recruitingN/AIIT

Impact of Oral Hygiene Instructions in the Resolution of Peri-implant Mucositis. A Randomized Clinical Trial

Peri-implant mucositis (PM) over dental implants is a highly prevalent disease characterized by inflammation of the peri-implant mucosa without loss of supporting bone around implants. If untreated, PM may progress into peri-implantitis, which may ultimately lead to implant loss. Multiple clinical studies have described a cause-effect relationship between the accumulation of biofilm and the development of PM and therefore effective oral hygiene practices and professional biofilm control are fundamental in their prevention and management. As it was stated in the latest expert consensus on the prevention and treatment of peri-implant diseases, up to date, the treatment of PM includes mechanical professional cleaning associated with oral hygiene instructions (OHI). However, the impact of OHI by itself is not known. This randomized clinical trial over 56 patients aims to identify if there is any superiority of individualized OHI and mechanical/physical instrumentation over OHI alone. The main objective is to evaluate the resolution of the disease, by means of reduction of modified bleeding index (mBI) 1 and 3 months after treatment. Secondary objectives include evaluating microbiological changes and determining if the extent of inflammation measured as the initial mBI could have any impact on PM resolution after different treatment modalities.In addition, the hypotheses formulated are as follows;
* The proper oral hygiene measures conducted by the patient after individualized OHI will achieve resolution of PM in a clinically relevant proportion of patients.
* The proper oral hygiene measures conducted by the patient after individualized OHI will reduce the expression of peri-implant pathogens as much as the combination of individualized OHI and professional mechanical debridement in a clinically relevant proportion of patients.
* The proper oral hygiene measures conducted by the patient after individualized OHI will reduce mBI as much as the combination of individualized OHI and professional mechanical debridement in a clinically relevant proportion of patients.
* The extent of inflammation measured as the mBI could be related with the degree of resolution of the disease according to the treatment.

开始日期2024-09-16

申办/合作机构

Universitat Internacional de Catalunya

100 项与 Universitat Internacional de Catalunya 相关的临床结果

登录后查看更多信息

0 项与 Universitat Internacional de Catalunya 相关的专利（医药）

登录后查看更多信息

2,113

项与 Universitat Internacional de Catalunya 相关的文献（医药）

2024-12-01·Clinical Biomechanics

Is the cadaveric model valid for examining orthopaedic manual therapy techniques? A cross-sectional comparative study in vivo and in vitro

Article

作者: Canet-Vintró, Max ; Bueno-Gracia, Elena ; Estébanez-de-Miguel, Elena ; Rodríguez-Sanz, Jacobo ; Gassó-Villarejo, Segi ; López-de-Celis, Carlos

BACKGROUNDCadaveric models are sometimes used to test the effect of manual techniques. We have not found any studies comparing the effect of tibiotarsal joint distraction on cadaveric models versus live models for clinical use. The aim was to compare the effect on tibiotarsal joint distraction movement when applying three force magnitudes of tibiotarsal axial traction technique force between a cadaveric model and volunteers. In addition, to compare the magnitude of force applied between the cadaveric model and volunteers. Finally, to assess the reliability of applying the same magnitude of force in three magnitudes of tibiotarsal axial traction force.METHODSA cross-sectional comparative study was conducted. Sixty ankle joints were in open-packed position and three magnitudes of tibiotarsal axial traction technique force were applied. Tibiotarsal joint distraction movement was measured with ultrasound.FINDINGSNo differences were found in applied force or tibiotarsal joint distraction between volunteers and cadavers in each magnitude of force (p > 0.05). The application of the technique showed moderate reliability for detecting low forces in both models. For medium and high force, it showed good reliability in the in vitro model and excellent reliability in the live model.INTERPRETATIONThe amount of distraction produced in the tibiotarsal joint was similar in volunteers and cadavers. The cadaveric model is a valid model for testing and investigating orthopaedic manual therapy techniques. The force applied was similar in the two models. Medium and high force detection showed good reliability, while low force showed moderate.

2024-12-01·Cellular and Molecular Life Sciences

A progesterone derivative linked to a stable phospholipid activates breast cancer cell response without leaving the cell membrane

Article

作者: Mateos, Nicolas ; Ferrari, Roberto ; Torreno-Pina, Juan Andres ; Wright, Roni H G ; Garcia-Parajo, Maria F ; Sanllehí, Pol ; Beato, Miguel ; Joglar, Jesús ; Abad, Beatriz ; Font-Mateu, Jofre ; Sot, Jesús ; Goñi, Félix M

AbstractIn hormone-responsive breast cancer cells, progesterone (P4) has been shown to act via its nuclear receptor (nPR), a ligand-activated transcription factor. A small fraction of progesterone receptor is palmitoylated and anchored to the cell membrane (mbPR) forming a complex with estrogen receptor alpha (ERα). Upon hormone exposure, either directly or via interaction with ERα, mbPR activates the SRC/RAS/ERK kinase pathway leading to phosphorylation of nPR by ERK. Kinase activation is essential for P4 gene regulation, as the ERK and MSK1 kinases are recruited by the nPR to its genomic binding sites and trigger chromatin remodeling. An interesting open question is whether activation of mbPR can result in gene regulation in the absence of ligand binding to intracellular progesterone receptor (iPR). This matter has been investigated in the past using P4 attached to serum albumin, but the attachment is leaky and albumin can be endocytosed and degraded, liberating P4. Here, we propose a more stringent approach to address this issue by ensuring attachment of P4 to the cell membrane via covalent binding to a stable phospholipid. This strategy identifies the actions of P4 independent from hormone binding to iPR. We found that a membrane-attached progestin can activate mbPR, the ERK signaling pathway leading to iPR phosphorylation, initial gene regulation and entry into the cell cycle, in the absence of detectable intracellular progestin.

2024-11-01·Journal of Stroke and Cerebrovascular Diseases

Radiological pattern in cryptogenic stroke/TIA patients with and without thrombophilia

Article

作者: Jovell, Laura ; Cocho, Dolores

BACKGROUNDThe radiological pattern of stroke patients with thrombophilia is unknown. Our aim is to compare the MRI radiological pattern of silent and acute lesions in cryptogenic stroke/TIA patients under 60 years of age with and without thrombophilia.METHODSCryptogenic stroke/TIA patients under 60 years of age hospitalized at our Stroke Unit during four years were consecutively included. Thrombophilia screening was performed at 3 months after stroke and verified 12 weeks later. The follow-up was performed at 3, 12 and 24 months. Radiological pattern was assessed with the Fazekas and van Swieten scales.RESULTSDuring four years, 185 cryptogenic stroke/TIA patients under 60 years of age were included; mean age was 51 years, 61% were female, with a follow-up of 22±3.2 months. Thrombophilia was detected in 20% of patients. We detected a significant increase of previous vascular events (29.7% vs 7.5%, p=.01) as well as lower hypercholesterolemia (27% vs 62.5% p=.003) in the thrombophilia group, without significant differences in other vascular risk factors or vascular recurrence during follow-up. Regarding the acute lesion, we did not detect significant differences between groups. The radiological pattern of silent lesions showed that the thrombophilia group presented more large confluent lesions (39.1% vs 19.2%, p=.02) with greater sparing of the anterior territory (0% vs 30%, p=.01).CONCLUSIONSOur data suggest a characteristic radiological pattern of silent lesions in cryptogenic stroke/TIA patients with thrombophilia, with more confluent lesions and less involvement of the anterior territory.

项与 Universitat Internacional de Catalunya 相关的新闻（医药）

2023-01-19

·GlobeNewswire-Health Care

Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection

-- First ‘living medicine’ to treat antibiotic-resistant Pseudomonas aeruginosa infections in the lung, a leading cause of mortality in hospital settings – -- Data demonstrate treatment reduced lung infection and increased survival in preclinical models, and support advancement of ongoing research leveraging platform in other serious lung diseases, including lung cancer and asthma -- BARCELONA, Spain, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Pulmobiotics SL, a biotechnology company pioneering novel live biotherapeutics for the treatment of lung diseases, and the Centre for Genomic Regulation (CRG), an international biomedical research institute of excellence whose mission is to discover and advance knowledge for the benefit of society, public health and economic prosperity, today announced the publication of preclinical results demonstrating that treatment using Pulmobiotics’ engineered live biotherapeutic significantly reduced antibiotic-resistant Pseudomonas aeruginosa infections in the lungs of mice, thereby improving survival rates, and dissolved biofilms formed on endotracheal tubes of patients with ventilator-associated pneumonia (VAP). These data highlight a promising new approach to treat antibiotic-resistant Pseudomonas aeruginosa lung infections, a leading cause of mortality in hospital settings, and could offer a potential alternative to the use of antibiotics that enable antibiotic resistance, a global public health crisis. Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases. This novel treatment approach uses a strain of attenuated live bacteria genetically engineered to produce specific enzymes with activity against Pseudomonas aeruginosa and the biofilms it forms which help the bacteria evade the immune system and antibiotics. This publication is the first time data has been described for a live biotherapeutic for the treatment of lung infection caused by Pseudomonas aeruginosa. The results are published in Nature Biotechnology and this research is supported by the European Research Council through an H2020 project and “la Caixa” Foundation through the CaixaResearch Health Call. “We have developed a battering ram that lays siege to antibiotic-resistant bacteria. The treatment punches holes in their cell walls, providing crucial entry points for antibiotics to invade and clear infections at their source,” said María Lluch, PhD, co-founder and Chief Scientific Officer at Pulmobiotics, Professor of Basic Sciences at the Universitat Internacional de Catalunya and co-corresponding author of the study. “This new treatment approach is working as intended, and, importantly, demonstrates strong activity against the difficult-to-penetrate bacterial biofilms. We believe these data represent a promising new strategy to address a leading cause of mortality in hospitals.” Key Findings Data demonstrate a signification reduction of Pseudomonas aeruginosa bacterial load in lungs of treated mice compared to controls. Histopathology assessment showed a significantly lower total score of lung lesions in lungs of treated mice compared to controls with less inflammation and less pneumonia indicating that treatment reduced Pseudomonas aeruginosa lung infection in the acute pneumonia mouse model.In mice with acute lung infections, treatment doubled their survival rate. 50% of mice given the treatment survived after eight days, the time period given for an infection to clear, whereas only 25% of the untreated mice survived.The treatment dissolved Pseudomonas aeruginosa biofilms formed on the surface of endotracheal tubes from VAP patients in the intensive care unit. Biofilms are clusters of bacteria that form impenetrable structures that are highly resistant to antibiotics. Treatment led to a significant reduction in Pseudomonas aeruginosa bacterial load with the Pulmobiotics treatment alone or in combination with ceftolozane/taxobactam antibiotics. These results demonstrate that the treatment has broad spectrum activity against biofilms formed by different multidrug-resistant Pseudomonas aeruginosa clinical strains.There were no signs of toxicity in the lungs of mice after a single, high dose of the treatment, and the treatment was cleared in four days.When tested as a prophylactic treatment against infection, the live biotherapeutic significantly reduced Pseudomonas aeruginosa in lungs of treated mice compared to untreated control mice. “Today’s publication is an exciting milestone for our company as it demonstrates the potential power of our live biotherapeutic platform in difficult-to-treat infectious diseases, as well as strong support for our belief that this approach can be applied to treat other serious lung diseases requiring continuous local delivery of a treatment” said Claudio Santos, PhD, Chief Executive Officer, Pulmobiotics. “We will continue to leverage our synthetic biology and microbiology engineering expertise to develop additional pipeline programs that address unmet clinical needs. Our recent funding awards from the European Union and Spanish government to advance treatments for additional lung diseases including NSCLC and asthma provide validation for this new modality and potential benefit for patients.” The European Innovation Council has selected Pulmobiotics’ research platform as a potential breakthrough technology for the treatment of non-small cell lung cancer (NSCLC). The funding will support research aimed at advancing live biotherapeutics that can overcome resistance that many patients develop to treatment with immune checkpoint inhibitors. Pulmobiotics has also received funding from the Spanish Ministry of Science and Innovation’s “Public-Private Collaboration Projects” to develop novel treatments for severe asthma in a consortium with the Centre for Genomic Regulation (CRG) and the Institute for Research in Biomedicine (IRB). About Pulmobiotics’ Live Biotherapeutic Treatment for Infectious Lung DiseaseThe live biotherapeutic was developed by modifying a bacterium, Mycoplasma pneumoniae, that is naturally present in the lung, removing its ability to cause disease and repurposing it to attack harmful microbes. It is designed to be administered alone or in combination with low dose antibiotics that would not work independently. The treatment offers an alternative to using high doses of antibiotics, which contribute to antibiotic resistance, a global public health threat. Unlike conventional treatments, an engineered bacterium may be able to deliver therapeutic molecules at the source of an infection without also adversely affecting healthy tissue, resulting in effective treatment with a low risk of side effects. Further preclinical testing and evaluation of the treatment is ongoing to support initiation of future clinical trials. The treatments being developed are designed to be administered using a nebulizer. About Ventilator-associated Pneumonia Ventilator-associated pneumonia (VAP) is a type of infection that affects critically ill patients who require intubation for breathing. Approximately 400,000 cases occur per year in the US and Europe and it is a significant cause of increased hospital stays and costs. The most common cause of VAP is Pseudomonas aeruginosa, a bacterium that accumulates on the surface of endotracheal tubes. In this environment, Pseudomonas aeruginosa forms biofilms that are extremely resistant to conventional treatments. To date, few treatments are available that can dissolve Pseudomonas aeruginosa biofilms, exacerbating mortality rates in intensive care units. About Pulmobiotics SLPulmobiotics SL is a biotechnology company pioneering novel live biotherapeutics for the treatment of lung diseases. Using a proprietary microbial engineering and synthetic biology toolbox, the Company engineers bacteria to expose antigens or deliver therapeutic agents in a controlled, local and continuous manner. Pulmobiotics SL is currently using this technology to discover and develop novel treatments for respiratory diseases, which are among the most common causes of severe illness and death worldwide, and is exploring its application in other disease areas. Pulmobiotics is a spin-off company from the Centre for Genomic Regulation (Barcelona - Spain) founded by experienced entrepreneurs and funded by Invivo Ventures. About the Centre for Genomic Regulation (CRG)The Centre for Genomic Regulation (CRG) is an international biomedical research institute of excellence, created in July 2000. It is a non-profit foundation funded by the Catalan Government through the Department of Business & Knowledge and the Department of Health, the Spanish Ministry of Science & Innovation, the "la Caixa" Banking Foundation, and includes the participation of Pompeu Fabra University. The mission of the CRG is to discover and advance knowledge for the benefit of society, public health and economic prosperity. The CRG believes that the medicine of the future depends on the groundbreaking science of today. This requires an interdisciplinary scientific team focused on understanding the complexity of life from the genome to the cell to a whole organism and its interaction with the environment, offering an integrated view of genetic diseases. Pulmobiotics Contacts: Claudio SantosChief Executive OfficerClaudio.santos@pulmobio.com Media:Mike Beyermike@redhousecomms.com+1-312-961-2502

微生物疗法

100 项与 Universitat Internacional de Catalunya 相关的药物交易

登录后查看更多信息

100 项与 Universitat Internacional de Catalunya 相关的转化医学

登录后查看更多信息